Niacin in Patients With Low HDL Cholesterol Levels Receiving Intensive Statin Therapy (AIM-HIGH)

This is the AIM-HIGH trial, reported here under its lead author. Its message is one of the most instructive negatives in lipid medicine, and it bears repeating.

The premise was attractive: patients with well-controlled LDL on statins still have “residual risk,” much of it associated with low HDL and high triglycerides — so add niacin, the drug that best corrects those numbers. Among 3,414 such patients, niacin did exactly that, raising HDL and lowering triglycerides and LDL further. Yet it produced no reduction in cardiovascular events, and the trial was halted early for futility.

The enduring lesson is the gap between a biomarker and a benefit. Improving the HDL and triglyceride numbers looked like progress on paper, but it did not translate into fewer heart attacks or strokes — undercutting the idea that raising HDL is therapeutically useful and reinforcing that LDL/apoB lowering remains the proven lever.

We rate the evidence strong as a randomized trial. It is the companion record of AIM-HIGH; its clinical significance lies in what it ruled out, narrowing the field to interventions that actually change outcomes.